Small Molecule Drug Discovery
Hit-to-Lead Services (H2L) - Higher Quality and Faster Cycle Times in the Era of Automation
SMALL MOLECULE DRUG DISCOVERY SERVICES
Hit optimization is a critical step in drug discovery to funnel into lead optimization. Select the most promising hits and leverage H2L, and automated chemical synthesis workflows for faster experimental screening cycles, decreased duration and hands on time, reducing the overall drug discovery timeline leading to promising preclinical candidates. Rapid turnaround of assay data on new small molecule structures will enable a higher number of data driven decisions about hit optimization per unit time thereby reducing the time to progress a project into the lead optimization stage.
Traditional outsourcing of compound synthesis and testing are time consuming and lead to long cycle times leaving less time to concentrate on compound design. Scientists leverage the Strateos’ remote access automated medicinal chemistry solutions to propel design-make-test-analyze cycles and drug discovery to new heights of speed and efficiency and deliver quality hits that progress to lead candidates.